Wattyl Pharmachems Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 21 Year, 6 Days
- Open Charges ₹ 1.75 Cr
- Satisfied Charges ₹ 2.50 M
About Wattyl Pharmachems
Wattyl Pharmachems Private Limited (WPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 February 2004 and has a history of 21 years. Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Home Appliances Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.75 Cr. The company has closed loans amounting to ₹2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Kamal Chand and Pushpa Bohara serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397TN2004PTC052463
-
Company No.
052463
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
03 Feb 2004
-
Date of AGM
-
-
Date of Balance Sheet
-
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Wattyl Pharmachems?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Chand
|
Director | 06-Dec-2006 | Current |
|
Pushpa Bohara
|
Director | 06-Dec-2006 | Current |
Financial Performance of Wattyl Pharmachems.
Enhance accessibility to Wattyl Pharmachems's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wattyl Pharmachems?
Unlock access to Wattyl Pharmachems's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Tricept Life Sciences Private LimitedKamal Chand is a mutual person
-
National Medicines Private LimitedKamal Chand is a mutual person
-
Tricept Pharmaceuticals Private Limited
Kamal Chand is a mutual person
Charges (Loans)
₹17.50 M
₹2.50 M
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Sep 2007 | State Bank Of India | ₹1.75 Cr | Open |
| 13 Jul 2006 | The South Indian Bank Ltd. | ₹2.50 M | Satisfied |
How Many Employees Work at Wattyl Pharmachems?
Unlock and access historical data on people associated with Wattyl Pharmachems, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wattyl Pharmachems, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wattyl Pharmachems's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
